THE001 (DPPG2-TSL-DOX), a thermosensitive liposomal formulation of doxorubicin, targets DOX-sensitive tumors, with locally advanced soft tissue sarcoma as the lead indication. A Phase I dose-escalation study of THE001 with regional hyperthermia is set to conclude in summer 2025.
Thermosome develops targeted tumor therapies combined with immune stimulation to enhance cancer treatment efficacy. Its approach increases local drug concentrations by around 15-fold and, when paired with regional hyperthermia, triggers an immune response.
Thermosome GmbH reported encouraging Phase I trial data for THE001 (DPPG2-TSL-DOX) combined with regional hyperthermia in treating soft tissue sarcomas.
The company aims to develop improved treatment options for seriously ill cancer patients with high unmet medical needs. It has assembled a team of entrepreneurs, scientists, and investors with industry experience.
Thermosome is a drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a new tumor targeting concept, which allows for increased local drug concentrations to achieve improved clinical treatment efficacy.
-> Duties to provide information in accordance with Article 13 GDPR – Applicants -> Informationspflichten bei einer Erhebung von Daten bei der betroffenen Person nach Art. 13 DSGVO – Bewerber
